by Orphagen Pharma | Jan 11, 2016 | News
Orphagen Pharmaceuticals, a privately-held emerging pharmaceutical company, described for the first time properties of small molecule antagonists to ROR-beta, an orphan nuclear receptor, at the Keystone Symposium on Nuclear Receptors taking place January 10-14 at...
by goldfishadmin | Oct 22, 2015 | News
Orphagen Pharmaceuticals, a privately-held pharmaceutical company, announced today that the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has awarded the company a highly competitive Phase 1 Small Business Innovative Research...
by goldfishadmin | Jul 1, 2015 | News
Orphagen Pharmaceuticals, a privately-held pharmaceutical company, announced today that the National Institutes of Health (NIH) National Cancer Institute (NCI) has awarded the company $224,954 under the Small Business Innovative Research (SBIR) program to identify...
by goldfishadmin | Mar 30, 2015 | News
Orphagen Pharmaceuticals announced today that Robin Jackman, CEO of Leading BioSciences, has been appointed to the Board of Directors. “Robin brings crucial experience to our Board in finance and fund-raising. This comes on top of his excellent record in guiding two...
by goldfishadmin | Sep 1, 2014 | News
Orphagen Pharmaceuticals, a privately-held pharmaceutical company, announced today that the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has awarded the company $223,229 under the Small Business...
by goldfishadmin | Jul 14, 2014 | News
Orphagen CEO, Scott Thacher, will speak tomorrow at the 17th Annual San Diego MedChem Syposium at UC San Diego Price Center Theatre. His presentation is entitled “First-in-Class Drug Discovery at Unexplored Orphan Nuclear Receptors.” The objective of this one-day...
